Evidence map›Paper›PMID 35553028›Full record

ArticlePharmacoEconomics2022

Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups.

Ellen Rafferty, Mike Paulden, Sarah A Buchan, Joan L Robinson, Julie A Bettinger, Manoj Kumar, Lawrence W Svenson, Shannon E MacDonald, Canadian Immunization Research Network (CIRN) investigators

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in PharmacoEconomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Respiratory syncytial virus vaccination strategies for older Canadian adults: a cost-utility analysis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2024
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ellen RaffertyFaculty of Nursing, University of Alberta, Edmonton, AB, Canada. erafferty@ihe.ca.ORCID 0000-0001-9974-8016
Mike PauldenSchool of Public Health, University of Alberta, Edmonton, AB, Canada.
Sarah A BuchanPublic Health Ontario, Toronto, ON, Canada.
Joan L RobinsonDepartment of Pediatrics, University of Alberta, Edmonton, AB, Canada.
Julie A BettingerVaccine Evaluation Center, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada.
Manoj KumarDepartment of Pediatrics, University of Alberta, Edmonton, AB, Canada.
Lawrence W SvensonSchool of Public Health, University of Alberta, Edmonton, AB, Canada.
Shannon E MacDonaldFaculty of Nursing, University of Alberta, Edmonton, AB, Canada.
Canadian Immunization Research Network (CIRN) investigators
University of Alberta · CAUniversity of British Columbia · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRespiratory syncytial virus (RSV) is a major cause of acute respiratory infection (ARI), with high morbidity and mortality worldwide. RSV costing and burden estimates can highlight the potential benefits of future vaccination programs and are essential for economic evaluations.

objectiveWe aimed to determine RSV healthcare costs across age groups and the overall disease burden of medically attended RSV in Canada.

methodsWe conducted a retrospective case-control study to estimate the attributable healthcare costs per RSV case in Alberta. We used two case definitions to capture diversity in case severity: laboratory-confirmed RSV and ARI attributable to RSV. Matching occurred on five criteria: (1) age, (2) urban/rural status, (3) sex, (4) prematurity and (5) Charlson Comorbidity Index score. We calculated the age-specific burden of medically attended RSV in Canada from 2010 to 2019 by multiplying the weekly age-specific incidence of medically attended ARI with the RSV positivity rate.

resultsCosts per laboratory-confirmed RSV case were (in Canadian dollars [CAD], year 2020 values) $CAD12,713 and 40,028 in the first 30 and 365 days following diagnosis, respectively, whereas a case of ARI potentially attributable to RSV cost $CAD316 and 915, in 30 and 365 days, respectively. Older (aged ≥ 65 years) and younger (aged < 90 days) age groups had the highest case costs. The average medically attended RSV incidence rate across nine seasons was 1743 cases per 100,000 people per year.

conclusionsRSV is a common and expensive infection at the extremes of life, and the development of immunization programs targeting older and younger ages may be important for the reduction of RSV burden and cost.

Indexed as

Respiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsAlbertaCase-Control StudiesCost of IllnessHealth Care CostsHospitalizationHumansInfantRetrospective Studies

Identifiers

PMID35553028
PMCPMC9130187
OpenAlexW4280518447

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.